| Turner Syndrome

Norditropin vs Nutropin AQ

Side-by-side clinical, coverage, and cost comparison for turner syndrome.

Deep comparison between: Norditropin vs Nutropin Aq Nuspin 10 with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsNutropin Aq Nuspin 10 has a higher rate of injection site reactions vs Norditropin based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Nutropin Aq Nuspin 10 but not Norditropin, including UnitedHealthcare

Category

Norditropin

Nutropin Aq Nuspin 10

At A Glance

RouteSC injection

FrequencyDaily

ClassRecombinant human growth hormone

RouteSC injection

FrequencyDaily

ClassRecombinant human growth hormone

Indications

Noonan Syndrome
Turner Syndrome
Prader-Willi Syndrome

Somatotropin deficiency
Turner Syndrome
Chronic Kidney Diseases

Dosing

Pediatric GHD 0.17-0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Noonan Syndrome Up to 0.46 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Turner Syndrome, SGA, ISS Up to 0.47 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Adult GHD (non-weight-based) Initiate at approximately 0.2 mg/day SC (range 0.15-0.3 mg/day); increase every 1-2 months by 0.1-0.2 mg/day based on clinical response and IGF-1 concentrations.

Adult GHD (weight-based) Initiate at 0.004 mg/kg/day SC; increase to a maximum of 0.016 mg/kg/day; not recommended for obese patients.

Somatotropin deficiency (pediatric) Up to 0.3 mg/kg/week divided into daily SC injections; pubertal patients may use up to 0.7 mg/kg/week divided daily.

Somatotropin deficiency (adult) Weight-based: starting dose up to 0.006 mg/kg/day SC, max 0.025 mg/kg/day (age <=35 years) or 0.0125 mg/kg/day (age >35 years); or non-weight-based: starting dose approximately 0.2 mg/day SC with gradual titration every 1-2 months.

Chronic Kidney Diseases Up to 0.35 mg/kg/week divided into daily SC injections; therapy may continue until renal transplantation.

Turner Syndrome Up to 0.375 mg/kg/week divided into equal doses 3 to 7 times per week by SC injection.

Contraindications

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Active malignancy
Hypersensitivity to somatropin or any excipient of NORDITROPIN
Active proliferative or severe non-proliferative diabetic retinopathy
Pediatric patients with closed epiphyses

Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome in children with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphysis (for growth promotion in pediatric patients)

Drug Interactions

267View drug interactions

Adverse Reactions

Most common (>=5%, adult onset GHD) Peripheral edema, edema, arthralgia, leg edema, myalgia, non-viral infection, paraesthesia, skeletal pain, headache, bronchitis, flu-like symptoms, hypertension, gastroenteritis, increased sweating, abnormal glucose tolerance, laryngitis, type 2 diabetes mellitus

Serious Increased mortality in acute critical illness, sudden death in pediatric PWS patients, neoplasms, intracranial hypertension, severe hypersensitivity reactions, fluid retention, slipped capital femoral epiphysis, pancreatitis

Postmarketing Anaphylactic reactions, angioedema, increase in cutaneous nevi, hypothyroidism, gynecomastia, hyperglycemia, osteonecrosis, increased blood alkaline phosphatase, decreased serum T4, pancreatitis, leukemia

Most common Edema or peripheral edema (adults with GHD), arthralgias (adults with GHD), otitis media and ear disorders (Turner syndrome), injection site discomfort (pediatric GHD)

Serious Intracranial hypertension, glucose intolerance, slipped capital femoral epiphysis, scoliosis progression, leukemia, pancreatitis, severe hypersensitivity reactions, hypothyroidism, hypoadrenalism, lipoatrophy

Postmarketing Anaphylaxis, angioedema, leukemia, gynecomastia (children), pancreatitis, slipped capital femoral epiphysis, osteonecrosis

Pharmacology

Recombinant human growth hormone (somatropin) binds to dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins including IGF-1, IGFBP-3, and acid-labile subunit, which stimulate chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal linear growth via effects on epiphyses of long bones.

Somatropin is a recombinant human growth hormone that binds to dimeric GH receptors on target cell membranes, triggering intracellular signal transduction; pharmacodynamic effects include skeletal growth and protein synthesis mediated via IGF-1, as well as direct effects such as lipolysis.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Norditropin